Randall Stanicky
Stock Analyst at RBC Capital
(1.39)
# 2,347
Out of 4,479 analysts
23
Total ratings
60%
Success rate
3.06%
Average return
Main Sectors:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $129 → $135 | $165.96 | -18.66% | 9 | Feb 4, 2021 | |
| PRGO Perrigo Company | Downgrades: Sector Perform | n/a | $25.99 | - | 4 | Jan 6, 2021 | |
| PFE Pfizer | Downgrades: Sector Perform | n/a | $27.83 | - | 2 | Dec 16, 2020 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | n/a | $105.09 | - | 2 | Nov 3, 2020 | |
| MRK Merck & Co. | Maintains: Sector Perform | n/a | $127.72 | - | 1 | Apr 1, 2020 | |
| AGRX Agile Therapeutics | Maintains: Outperform | n/a | $1.41 | - | 1 | Feb 18, 2020 | |
| AMRX Amneal Pharmaceuticals | Maintains: Sector Perform | n/a | $6.54 | - | 1 | Jan 2, 2020 | |
| OPTN OptiNose | Initiates: Outperform | n/a | $1.04 | - | 1 | Nov 7, 2017 | |
| TEVA Teva Pharmaceutical | Downgrades: Underperform | n/a | $16.55 | - | 1 | Aug 4, 2017 | |
| PCRX Pacira BioSciences | Initiates: Outperform | n/a | $22.74 | - | 1 | Apr 13, 2017 |
AbbVie
Feb 4, 2021
Maintains: Outperform
Price Target: $129 → $135
Current: $165.96
Upside: -18.66%
Perrigo Company
Jan 6, 2021
Downgrades: Sector Perform
Price Target: n/a
Current: $25.99
Upside: -
Pfizer
Dec 16, 2020
Downgrades: Sector Perform
Price Target: n/a
Current: $27.83
Upside: -
Jazz Pharmaceuticals
Nov 3, 2020
Maintains: Outperform
Price Target: n/a
Current: $105.09
Upside: -
Merck & Co.
Apr 1, 2020
Maintains: Sector Perform
Price Target: n/a
Current: $127.72
Upside: -
Agile Therapeutics
Feb 18, 2020
Maintains: Outperform
Price Target: n/a
Current: $1.41
Upside: -
Amneal Pharmaceuticals
Jan 2, 2020
Maintains: Sector Perform
Price Target: n/a
Current: $6.54
Upside: -
OptiNose
Nov 7, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.04
Upside: -
Teva Pharmaceutical
Aug 4, 2017
Downgrades: Underperform
Price Target: n/a
Current: $16.55
Upside: -
Pacira BioSciences
Apr 13, 2017
Initiates: Outperform
Price Target: n/a
Current: $22.74
Upside: -